Table 3.

Emerging therapies for INOCA.

Study	Clinical trial identifier	Inclusion criteria	n	Intervention	Primary outcome	Current progress
PRIZE	NCT04097314	Microvascular angina	356	Zibotentan 10 mg daily	Change in exercise treadmill test time	Ongoing. Expected completion November 2022
		Age $\ge$18 years old
TIC-2	ACTRN12616000388415	Coronary slow flow in absence of obstructive coronary artery disease	35	Ticagrelor 90 mg twice daily for 4 weeks	Change in angina symptom frequency	Stopped early due to resource constraints
		Angina symptoms $\ge$3 times in the 2 weeks prior to enrolment				Data collected currently subject to analysis
		Age $\ge$18 years old
WARRIOR	NCT03417388	Non-obstructive coronary artery disease	4422	High dose atorvastatin/rosuvastatin + lisinopril or losartan + lifestyle counselling $\pm$ aspirin vs primary prevention risk factor therapy	All-cause mortality during 3-year study period	Ongoing. Expected completion December 2023
		Female
		Age 18–100 years old
COSIMA	NCT04606459	Evidence of microvascular disease	144	Coronary sinus reducer	Change in Canadian Cardiovascular Society angina class $\ge$2 within 6-month study period	Ongoing. Expected completion October 2029
		Refractory angina
		Canadian Cardiovascular Society angina class III–IV
		Age $\ge$18 and $\le$85 years old
Rhodiola Rosea for coronary microvascular disease	NCT04218916	Typical angina pectoris with normal coronaries or a stenosis 20% and an anterior descending coronary flow reserve 2.0	114	0.56 g Rhodiola Rosea capsules three times a day	Change in coronary flow reserve after 1 year	Ongoing. Expected completion January 2023
		Age 40–75 years old

INOCA, Ischemia with Non-Obstructive Coronary Artery Disease PRIZE, Precision Medicine With Zibotentan in Microvascular Angina; TIC-2, Ticagrelor in Coronary Microvascular Dysfunction 2 Trial; WARRIOR, Women’s Ischemia Trial to Reduce Events In Non-Obstructive Coronary Artery Disease; COSIMA, Coronary Sinus Reducer for the Treatment of Refractory Microvascular Angina.